- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 543KB)
Nirsevimab – July 2024
Nirsevimab; Solution for injection 50 mg in 0.5 mL pre filled syringe, Solution for injection 100 mg in 1 mL pre filled syringe; Beyfortus®
Last updated
30 May 2025